Shots:
- Polpharma has entered into a global licensing agreement with Fresenius Kabi to commercialize PB016, a biosimilar version of Takeda’s Entyvio (vedolizumab) for the treatment of mod. to sev. ulcerative colitis & Crohn’s disease
- As per the deal, Fresenius will obtain global commercialization rights to PB016, excl. Middle East & North Africa, while Polpharma will handle development & manufacturing
- Vedolizumab is a humanized monoclonal antibody that targets α4β7 integrin to block its interaction with MAdCAM-1 for producing anti-inflammatory effect
Ref: Businesswire | Image: Polpharma Biologics and Fresenius Kabi| Press Release
Related News:- Alteogen’s Eyluxvi (Biosimilar, Eylea) Receives the CHMP’s Positive Opinion for Retinal Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
